Bayer: UBS confident about pharma business
(CercleFinance.com) - UBS maintains its "buy" rating on Bayer shares, nudging up its target price for them from E99 to E100, with the latter representing upside potential for 79% for the German health and agrochemicals group's stock.
"Pieces of the Bayer pharma puzzle are coming together," the broker said. "Nubeqa is trending well. Elinzanetant might add another piece later this year," it adds.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"Pieces of the Bayer pharma puzzle are coming together," the broker said. "Nubeqa is trending well. Elinzanetant might add another piece later this year," it adds.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.